CN117615755A - 包含美沙酮的胃驻留系统 - Google Patents

包含美沙酮的胃驻留系统 Download PDF

Info

Publication number
CN117615755A
CN117615755A CN202280046388.1A CN202280046388A CN117615755A CN 117615755 A CN117615755 A CN 117615755A CN 202280046388 A CN202280046388 A CN 202280046388A CN 117615755 A CN117615755 A CN 117615755A
Authority
CN
China
Prior art keywords
gastric
segment
arms
resident system
drug eluting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280046388.1A
Other languages
English (en)
Chinese (zh)
Inventor
E·贝金
P·夸顿
J·卡特斯特拉
D·阿尔特雷特尔
J·J·蒙特斯科
M·皮帕拉德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lindera Treatment Co
Original Assignee
Lindera Treatment Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lindera Treatment Co filed Critical Lindera Treatment Co
Publication of CN117615755A publication Critical patent/CN117615755A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
CN202280046388.1A 2021-05-05 2022-05-04 包含美沙酮的胃驻留系统 Pending CN117615755A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163184760P 2021-05-05 2021-05-05
US63/184,760 2021-05-05
PCT/US2022/072115 WO2022236289A1 (en) 2021-05-05 2022-05-04 Gastric residence systems comprising methadone

Publications (1)

Publication Number Publication Date
CN117615755A true CN117615755A (zh) 2024-02-27

Family

ID=83932453

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280046388.1A Pending CN117615755A (zh) 2021-05-05 2022-05-04 包含美沙酮的胃驻留系统

Country Status (8)

Country Link
US (1) US20240335400A1 (https=)
EP (1) EP4333824A4 (https=)
JP (1) JP2024517829A (https=)
CN (1) CN117615755A (https=)
AU (1) AU2022270208A1 (https=)
CA (1) CA3216743A1 (https=)
IL (1) IL308211A (https=)
WO (1) WO2022236289A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020117855A1 (en) 2018-12-03 2020-06-11 Lyndra, Inc. Stomach simulating device
BR112021018496A2 (pt) 2019-03-20 2021-11-30 Lyndra Therapeutics Inc Cápsulas e revestimento de cápsula para formas de dosagem de residência gástrica
AU2020242062B2 (en) 2019-03-20 2025-12-11 Nortiva Bio, Inc. Coatings for gastric residence dosage forms

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011276170B2 (en) * 2010-07-06 2016-03-10 Grunenthal Gmbh Novel gastro- retentive dosage forms comprising a GABA Analog and an opioid
AU2013369379B2 (en) * 2012-12-27 2018-03-15 Hennig Arzneimittel Gmbh & Co. Kg Monolithic dosage form for the modified release of an active ingredient combination
US11576859B2 (en) * 2015-10-23 2023-02-14 Lyndra Therapeutics, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
WO2017100367A1 (en) * 2015-12-08 2017-06-15 Lyndra, Inc. Geometric configurations for gastric residence systems
SG11201901294QA (en) * 2016-09-13 2019-03-28 Alar Pharmaceuticals Inc Sustained-release buprenorphine formulations background of invention
JP2019532947A (ja) * 2016-09-30 2019-11-14 リンドラ，インコーポレイティド アダマンタン系薬物の持続的送達のための胃内滞留システム
CA3066658A1 (en) * 2017-06-09 2018-12-13 Lyndra, Inc. Gastric residence systems with release rate-modulating films

Also Published As

Publication number Publication date
AU2022270208A1 (en) 2023-12-07
EP4333824A1 (en) 2024-03-13
IL308211A (en) 2024-01-01
JP2024517829A (ja) 2024-04-23
CA3216743A1 (en) 2022-11-10
EP4333824A4 (en) 2025-04-09
WO2022236289A1 (en) 2022-11-10
US20240335400A1 (en) 2024-10-10

Similar Documents

Publication Publication Date Title
JP6550157B2 (ja) Ｇａｂａ類似体及びオピオイドを含む新規胃内滞留型剤形
AU2008282900B2 (en) Pulsatile gastric retentive dosage forms
CN117615755A (zh) 包含美沙酮的胃驻留系统
US20240390270A1 (en) Gastric residence systems for administration of risperidone
CN119925721A (zh) 用于胃驻留系统的材料结构
US20120015031A1 (en) Novel gastro-retentive dosage forms
CN102365085A (zh) 具有降低的醇相互作用的抗滥用的熔体挤出制剂
CN101370485A (zh) 用于滥用药物给药的剂型和方法
CN117615754A (zh) 包含丁丙诺啡和纳洛酮的胃驻留系统
CN120303029A (zh) 使用胃驻留系统的利培酮剂量方案
US20250339368A1 (en) Dosage forms for gastric retention
CN117083059A (zh) 用于利培酮施用的胃滞留系统
CN118871091A (zh) 用于胃滞留的剂型
TW202500122A (zh) 用於胃滯留系統之材料架構

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination